They stated very clearly that it was halted because they were unlikely to meet the primary endpoint (30 day mortality) at the target of a 43 percent mortality reduction. Maybe by the 3rd interim, they were already noticing reduced mortality at 60 days but not 30, and recommended the trial be stopped so those good results could be released sooner - so the product could be made available to the public sooner. The goal of NIH wasn't pure science, or MSB commercial interests, it was to find treatments urgently needed for the pandemic. DSMB may have been instructed to recommend a halt in this type of scenario, even if it wasn't the pre-specified "overwhelming efficacy" everyone had been hoping for.
Ann: COVID ARDS Trial Topline 60-Day Results, page-540
-
- There are more pages in this discussion • 1,089 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
96.0¢ |
Change
0.035(3.78%) |
Mkt cap ! $1.101B | |||
| Open | High | Low | Value | Volume |
| 94.0¢ | 96.5¢ | 93.5¢ | $1.832M | 1.918M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 16 | 218659 | 95.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 96.0¢ | 67237 | 10 |
View Market Depth
| Last trade - 11.55am 09/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |